FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912205029> ?p ?o ?g. }

• W2912205029 endingPage "492" @default.
• W2912205029 startingPage "481" @default.
• W2912205029 abstract "Rationale: Needle-free intranasal vaccines offer major potential advantages, especially against pathogens entering via mucosal surfaces. As yet, there is no effective vaccine against respiratory syncytial virus (RSV), a ubiquitous pathogen of global importance that preferentially infects respiratory epithelial cells; new strategies are urgently required.Objectives: Here, we report the safety and immunogenicity of a novel mucosal RSV F protein vaccine linked to an immunostimulatory bacterium-like particle (BLP).Methods: In this phase I, randomized, double-blind, placebo-controlled trial, 48 healthy volunteers, aged 18–49 years, were randomly assigned to receive placebo or SynGEM (low or high dose) intranasally by prime-boost administration. The primary outcome was safety and tolerability, with secondary objectives assessing virus-specific immunogenicity.Measurements and Main Results: There were no significant differences in adverse events between placebo and vaccinated groups. SynGEM induced systemic plasmablast responses and significant, durable increases in RSV-specific serum antibody in healthy, seropositive adults. Volunteers given low-dose SynGEM (140 μg F, 2 mg BLP) required a boost at Day 28 to achieve plateau responses with a maximum fold change of 2.4, whereas high-dose recipients (350 μg F, 5 mg BLP) achieved plateau responses with a fold change of 1.5 after first vaccination that remained elevated up to 180 days after vaccination, irrespective of further boosting. Palivizumab-like antibodies were consistently induced, but F protein site ∅-specific antibodies were not detected, and virus-specific nasal IgA responses were heterogeneous, with the strongest responses in individuals with lower pre-existing antibody levels.Conclusions: SynGEM is thus the first nonreplicating intranasal RSV subunit vaccine to induce persistent antibody responses in human volunteers.Clinical trials registered with www.clinicaltrials.gov (NCT02958540)." @default.
• W2912205029 created "2019-02-21" @default.
• W2912205029 creator A5001928080 @default.
• W2912205029 creator A5014502334 @default.
• W2912205029 creator A5015892119 @default.
• W2912205029 creator A5018949285 @default.
• W2912205029 creator A5023371865 @default.
• W2912205029 creator A5045351075 @default.
• W2912205029 creator A5048221194 @default.
• W2912205029 creator A5052589342 @default.
• W2912205029 creator A5058652376 @default.
• W2912205029 creator A5062785780 @default.
• W2912205029 creator A5068632388 @default.
• W2912205029 creator A5084250251 @default.
• W2912205029 creator A5086901440 @default.
• W2912205029 date "2019-08-15" @default.
• W2912205029 modified "2023-10-14" @default.
• W2912205029 title "Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial" @default.
• W2912205029 cites W1975737434 @default.
• W2912205029 cites W1978777163 @default.
• W2912205029 cites W1981732883 @default.
• W2912205029 cites W1990429464 @default.
• W2912205029 cites W1991558810 @default.
• W2912205029 cites W2002392006 @default.
• W2912205029 cites W2018164772 @default.
• W2912205029 cites W2022949657 @default.
• W2912205029 cites W2035985071 @default.
• W2912205029 cites W2041704343 @default.
• W2912205029 cites W2076213364 @default.
• W2912205029 cites W2111890970 @default.
• W2912205029 cites W2114653354 @default.
• W2912205029 cites W2116555540 @default.
• W2912205029 cites W2130386320 @default.
• W2912205029 cites W2142041681 @default.
• W2912205029 cites W2164616921 @default.
• W2912205029 cites W2270869679 @default.
• W2912205029 cites W2286655369 @default.
• W2912205029 cites W2336491233 @default.
• W2912205029 cites W2576577186 @default.
• W2912205029 cites W2727509207 @default.
• W2912205029 cites W2742906250 @default.
• W2912205029 cites W2744865192 @default.
• W2912205029 cites W2755200049 @default.
• W2912205029 cites W2759073829 @default.
• W2912205029 cites W2789501639 @default.
• W2912205029 cites W2790138131 @default.
• W2912205029 cites W4211207275 @default.
• W2912205029 doi "https://doi.org/10.1164/rccm.201810-1921oc" @default.
• W2912205029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6701032" @default.
• W2912205029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30753101" @default.
• W2912205029 hasPublicationYear "2019" @default.
• W2912205029 type Work @default.
• W2912205029 sameAs 2912205029 @default.
• W2912205029 citedByCount "26" @default.
• W2912205029 countsByYear W29122050292019 @default.
• W2912205029 countsByYear W29122050292020 @default.
• W2912205029 countsByYear W29122050292021 @default.
• W2912205029 countsByYear W29122050292022 @default.
• W2912205029 countsByYear W29122050292023 @default.
• W2912205029 crossrefType "journal-article" @default.
• W2912205029 hasAuthorship W2912205029A5001928080 @default.
• W2912205029 hasAuthorship W2912205029A5014502334 @default.
• W2912205029 hasAuthorship W2912205029A5015892119 @default.
• W2912205029 hasAuthorship W2912205029A5018949285 @default.
• W2912205029 hasAuthorship W2912205029A5023371865 @default.
• W2912205029 hasAuthorship W2912205029A5045351075 @default.
• W2912205029 hasAuthorship W2912205029A5048221194 @default.
• W2912205029 hasAuthorship W2912205029A5052589342 @default.
• W2912205029 hasAuthorship W2912205029A5058652376 @default.
• W2912205029 hasAuthorship W2912205029A5062785780 @default.
• W2912205029 hasAuthorship W2912205029A5068632388 @default.
• W2912205029 hasAuthorship W2912205029A5084250251 @default.
• W2912205029 hasAuthorship W2912205029A5086901440 @default.
• W2912205029 hasBestOaLocation W29122050292 @default.
• W2912205029 hasConcept C126322002 @default.
• W2912205029 hasConcept C142724271 @default.
• W2912205029 hasConcept C159047783 @default.
• W2912205029 hasConcept C159654299 @default.
• W2912205029 hasConcept C197934379 @default.
• W2912205029 hasConcept C202061045 @default.
• W2912205029 hasConcept C203014093 @default.
• W2912205029 hasConcept C204787440 @default.
• W2912205029 hasConcept C22070199 @default.
• W2912205029 hasConcept C2522874641 @default.
• W2912205029 hasConcept C27081682 @default.
• W2912205029 hasConcept C2778375690 @default.
• W2912205029 hasConcept C2778644256 @default.
• W2912205029 hasConcept C2779341262 @default.
• W2912205029 hasConcept C2780868878 @default.
• W2912205029 hasConcept C2991744798 @default.
• W2912205029 hasConcept C71924100 @default.
• W2912205029 hasConcept C85663871 @default.
• W2912205029 hasConcept C8891405 @default.
• W2912205029 hasConceptScore W2912205029C126322002 @default.
• W2912205029 hasConceptScore W2912205029C142724271 @default.
• W2912205029 hasConceptScore W2912205029C159047783 @default.
• W2912205029 hasConceptScore W2912205029C159654299 @default.
• W2912205029 hasConceptScore W2912205029C197934379 @default.

• next